title: Pharmacotherapies for lipid modification: beyond the statins.
abstract: The widespread clinical use of statins has contributed to significant reductions in the rate of cardiovascular morbidity and mortality over the past 3 decades, and statins are considered first-line therapy for the prevention and treatment of atherosclerotic vascular disease. Nevertheless, various other lipid-lowering agents can provide clinical benefit by supplementing or augmenting statin therapy in patients with severe hypercholesterolaemia or mixed dyslipidaemia, or by providing an alternative for patients who are intolerant to statins. Bile acid resins and niacin were prescribed for lipid modification for years before the introduction of the statins, and new data continue to emerge regarding their use in different patient groups and for specific conditions. Ezetimibe can be appropriate for patients whose primary lipid abnormality is an elevated LDL-cholesterol level, whereas the fibrates seem to be most beneficial in patients with low levels of HDL cholesterol and elevated triglycerides. At the end of 2012 and the beginning of 2013, the first microsomal triglyceride transfer protein inhibitor, lomitapide, and the first antisense therapy to target apolipoprotein B, mipomersen, were approved for the treatment of individuals with extremely elevated LDL-cholesterol levels caused by homozygous familial hypercholesterolaemia. Although two agents in the experimental class of cholesteryl ester transfer protein inhibitors have failed to show a benefit in clinical trials, newer drugs in this class could provide an additional strategy to address residual cardiovascular risk in patients treated with statins.
authors: Weill Cornell Medical College, 1305 York Avenue, Y-805, New York, NY 10021, USA.
authors: Antonio M
authors: AM
authors: Gotto
authors: Jennifer E
authors: JE
authors: Moon
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids
references: JAMA. 1984 Jan 20;251(3):351-64
references: 6361299
references: Eur Heart J. 2012 Apr;33(7):857-65
references: 22345126
references: Nutr Rev. 2012 Jun;70(6):357-66
references: 22646128
references: Int J Clin Pract. 2009 Sep;63(9):1369-77
references: 19691622
references: J Am Coll Cardiol. 1986 Dec;8(6):1245-55
references: 3782631
references: Clin Ther. 2010 Apr;32(4):615-25
references: 20435231
references: N Engl J Med. 2008 Apr 3;358(14):1431-43
references: 18376000
references: Cochrane Database Syst Rev. 2012 Dec 12;12:CD009361
references: 23235674
references: Diabetes Care. 2009 Mar;32(3):493-8
references: 18984774
references: Am J Cardiol. 2014 Jan 1;113(1):76-83
references: 24188894
references: Curr Opin Lipidol. 2012 Feb;23(1):43-55
references: 22186660
references: Lancet. 2010 May 29;375(9729):1875-84
references: 20462635
references: J Lipid Res. 2011 Nov;52(11):1965-73
references: 21841206
references: J Clin Invest. 1994 Nov;94(5):1872-82
references: 7962532
references: Eur Heart J. 2012 Jun;33(12):1451-8
references: 22634577
references: Clin Pharmacol Ther. 2012 Jan;91(1):109-22
references: 22130116
references: Circulation. 2004 Jul 13;110(2):227-39
references: 15249516
references: Circulation. 2009 Dec 15;120(24):2414-20
references: 19948972
references: Eur Heart J. 2011 Jun;32(11):1345-61
references: 21531743
references: Circulation. 2012 Nov 6;126(19):2283-92
references: 23060426
references: N Engl J Med. 2012 Nov 29;367(22):2089-99
references: 23126252
references: N Engl J Med. 2011 Jan 13;364(2):127-35
references: 21226578
references: Science. 1992 Nov 6;258(5084):999-1001
references: 1439810
references: J Am Coll Cardiol. 2011 Mar 1;57(9):1111-9
references: 21255957
references: N Engl J Med. 2007 Nov 22;357(21):2109-22
references: 17984165
references: Circulation. 1992 Jan;85(1):37-45
references: 1728471
references: Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816
references: 23440795
references: Am J Cardiol. 2012 Feb 1;109(3):364-9
references: 22112743
references: N Engl J Med. 2010 Apr 29;362(17):1563-74
references: 20228404
references: Cleve Clin J Med. 2011 Jun;78(6):393-403
references: 21632911
references: J Lipid Res. 2012 Dec;53(12):2515-24
references: 22811413
references: Curr Opin Lipidol. 2011 Aug;22(4):288-95
references: 21587074
references: Circ Cardiovasc Genet. 2009 Feb;2(1):26-33
references: 20031564
references: J Lipid Res. 2013 Jan;54(1):134-51
references: 23118444
references: PLoS One. 2012;7(11):e49006
references: 23152839
references: J Am Coll Cardiol. 2010 Jun 8;55(23):2580-9
references: 20513599
references: J Lipid Res. 2010 Sep;51(9):2739-52
references: 20458119
references: J Am Coll Cardiol. 2011 Apr 19;57(16):1666-75
references: 21492764
references: Curr Opin Lipidol. 2010 Dec;21(6):481-6
references: 21042216
references: J Lipid Res. 2003 Jan;44(1):22-32
references: 12518019
references: N Engl J Med. 2011 Dec 15;365(24):2255-67
references: 22085343
references: N Engl J Med. 2009 Nov 26;361(22):2113-22
references: 19915217
references: N Engl J Med. 1999 Aug 5;341(6):410-8
references: 10438259
references: J Clin Pharmacol. 2009 Jul;49(7):838-47
references: 19443679
references: Lancet. 2005 Nov 26;366(9500):1849-61
references: 16310551
references: Lancet. 2012 Aug 11;380(9841):581-90
references: 22607822
references: Lancet. 2010 Mar 20;375(9719):998-1006
references: 20227758
references: J Am Coll Cardiol. 2006 Mar 7;47(5):992-7
references: 16516083
references: J Lipid Res. 2010 Dec;51(12):3443-54
references: 20861162
references: Nat Clin Pract Cardiovasc Med. 2008 Aug;5(8):497-505
references: 18506154
references: J Clin Invest. 1996 Jun 15;97(12):2917-23
references: 8675707
references: Circulation. 2000 Apr 25;101(16):1907-12
references: 10779455
references: J Am Coll Cardiol. 2011 Mar 1;57(9):1120-1
references: 21255956
references: Circulation. 2000 Jul 4;102(1):21-7
references: 10880410
references: Eur Heart J. 2013 May;34(17):1279-91
references: 23444397
references: Curr Med Res Opin. 2011 Jun;27(6):1191-210
references: 21473671
references: N Engl J Med. 2007 Jan 11;356(2):148-56
references: 17215532
references: Arteriosclerosis. 1988 Nov-Dec;8(6):737-41
references: 3196218
references: Atherosclerosis. 2010 May;210(1):35-40
references: 20005515
references: Circulation. 2011 May 24;123(20):2292-333
references: 21502576
references: N Engl J Med. 1990 Nov 1;323(18):1234-8
references: 2215607
references: J Intern Med. 2009 May;265(5):568-80
references: 19141093
references: Lancet. 2011 Oct 29;378(9802):1547-59
references: 21908036
references: JAMA. 2008 Jun 18;299(23):2777-88
references: 18560005
references: J Lipid Res. 2013 Feb;54(2):467-72
references: 23172660
references: Sci Transl Med. 2012 Aug 22;4(148):148ra115
references: 22914621
references: Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):183-8
references: 19262375
references: J Am Coll Cardiol. 2008 Dec 16;52(25):2198-205
references: 19095139
references: Atherosclerosis. 2010 Jun;210(2):353-61
references: 20079494
references: Prog Lipid Res. 2012 Oct;51(4):314-24
references: 22609245
references: J Am Coll Cardiol. 2012 Feb 7;59(6):572-82
references: 22300691
references: Am J Cardiovasc Drugs. 2011 Jun 1;11(3):179-87
references: 21619381
references: Endocrinol Metab Clin North Am. 2009 Mar;38(1):79-97
references: 19217513
references: J Am Coll Cardiol. 2010 Jun 15;55(24):2727-35
references: 20538165
references: Lancet. 2012 Aug 11;380(9841):572-80
references: 22607825
references: Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):582-8
references: 22207729
references: Lancet. 2011 Jun 25;377(9784):2181-92
references: 21663949
references: JAMA. 2001 May 16;285(19):2486-97
references: 11368702
references: N Engl J Med. 2007 Sep 27;357(13):1301-10
references: 17898099
references: Circ Res. 2008 Nov 7;103(10):1084-91
references: 18832751
references: N Engl J Med. 2010 Dec 16;363(25):2406-15
references: 21082868
references: J Lipid Res. 2011 Dec;52(12):2169-2176
references: 21957197
references: J Clin Lipidol. 2011 Nov-Dec;5(6):441-9
references: 22108147
references: Eur Heart J. 2013 Apr;34(13):962-71
references: 23416791
references: Am J Cardiol. 2012 Sep 15;110(6):817-22
references: 22683042
references: Lancet. 2001 Mar 24;357(9260):905-10
references: 11289345
references: Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1430-8
references: 20448206
references: N Engl J Med. 1987 Nov 12;317(20):1237-45
references: 3313041
references: Biochim Biophys Acta. 2012 Jul;1821(7):964-72
references: 22480541
references: N Engl J Med. 2008 Sep 25;359(13):1343-56
references: 18765433
references: Lancet. 2010 Jul 31;376(9738):333-9
references: 20655105
references: Lancet. 2013 Jan 5;381(9860):40-6
references: 23122768
references: J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62
references: 23770179
references: J Am Coll Cardiol. 2012 Nov 13;60(20):2041-8
references: 23083790
references: Lancet. 2010 Nov 13;376(9753):1670-81
references: 21067804
references: Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):160-7
references: 12588754
references: JAMA. 2011 Nov 16;306(19):2099-109
references: 22089718